Illumina (NASDAQ:ILMN) Issues Earnings Results, Beats Expectations By $0.10 EPS

Illumina (NASDAQ:ILMN) posted its quarterly earnings results on Thursday. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10, FiscalAI reports. Illumina had a net margin of 19.57% and a return on equity of 31.04%. During the same quarter last year, the company posted $0.97 earnings per share. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina updated its FY 2026 guidance to 5.150-5.300 EPS.

Here are the key takeaways from Illumina’s conference call:

• Illumina beat Q1 guidance on revenue, margins, and EPS and raised 2026 guidance to $4.52–$4.62B revenue, non‑GAAP operating margin of 23.4%–23.6%, and EPS of $5.15–$5.30, citing Q1 outperformance.
• Demand for the NovaSeq X accelerated with over 80 placements in Q1 (≈20 more YoY) and sequencing consumables grew, led by clinical consumables which rose ~20% ex‑China and represented >65% of consumables revenue.
• Management said they were supply‑constrained on NovaSeq X units and expect Q2 operating margins near ~22% due to a higher instrument mix, inflationary component/freight costs and a full quarter of SomaLogic, though they expect margin improvement in H2.
• Illumina closed the SomaLogic acquisition (~$363M net), reported the business performing in line with expectations, and the board authorized an additional $1.5B in share repurchases while gross leverage sits around 1.5x LTM EBITDA.

Illumina Trading Up 5.3%

NASDAQ ILMN traded up $6.37 during trading on Thursday, hitting $126.74. The company had a trading volume of 2,412,187 shares, compared to its average volume of 1,296,474. The company has a current ratio of 2.08, a quick ratio of 1.72 and a debt-to-equity ratio of 0.55. Illumina has a one year low of $73.86 and a one year high of $155.53. The company has a market cap of $19.25 billion, a price-to-earnings ratio of 23.26, a price-to-earnings-growth ratio of 2.31 and a beta of 1.49. The company’s fifty day moving average is $125.68 and its 200-day moving average is $126.43.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q1 results beat estimates: Illumina reported non‑GAAP EPS of $1.15 vs. consensus ~$1.05 and revenue of $1.09B (+4.8% y/y), signaling steady top‑line and margin improvement. Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
• Positive Sentiment: Raised FY2026 EPS guidance and revenue range: Company gave FY EPS guidance of $5.150–5.300 (above consensus ~5.12) and revenue guidance slightly above estimates — a signal management expects continued profitability. Illumina lifts 2026 outlook and expands share buybacks
• Positive Sentiment: Large share‑repurchase authorization: Board approved an additional $1.5B in buybacks, which supports EPS and signals capital return priority. Illumina Reports Financial Results for First Quarter of Fiscal Year 2026
• Positive Sentiment: Operational strength: GAAP and non‑GAAP operating margins improved (non‑GAAP operating margin ~21.9%) and ROE is strong, underpinning earnings quality. Illumina Q1 Profit Rises On Higher Revenue, Improved Margins
• Neutral Sentiment: Product/tech update could be a longer‑term catalyst: DRAGEN v4.5 (ML‑powered genomics software) was highlighted as a meaningful upgrade for variant calling and multiomic workflows — positive for positioning but benefits are gradual. Will DRAGEN v4.5’s ML-Powered Genomics Upgrade Reshape Illumina’s (ILMN) Precision Medicine Narrative?
• Neutral Sentiment: Conference call / disclosures: Management provided detailed slides and a transcript that clarify growth drivers and assumptions — useful for modeling but no surprise items were flagged. Listen to Conference Call
• Negative Sentiment: Modest revenue growth: Revenue rose only ~4.8% y/y (ROW organic ~3.5%), underscoring that top‑line expansion remains modest and may limit upside versus higher‑growth biotech peers. Illumina (NASDAQ:ILMN) Posts Better-Than-Expected Sales In Q1 CY2026

Insider Buying and Selling

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares in the company, valued at approximately $1,896,173.78. This represents a 12.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ILMN. Invesco Ltd. raised its holdings in Illumina by 97.0% in the 4th quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after purchasing an additional 1,352,731 shares in the last quarter. AQR Capital Management LLC raised its holdings in Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares in the last quarter. Morgan Stanley raised its holdings in Illumina by 66.0% in the 4th quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock worth $331,710,000 after purchasing an additional 1,005,474 shares in the last quarter. First Trust Advisors LP raised its holdings in Illumina by 87.2% in the 4th quarter. First Trust Advisors LP now owns 870,610 shares of the life sciences company’s stock worth $114,189,000 after purchasing an additional 405,652 shares in the last quarter. Finally, State Street Corp grew its position in shares of Illumina by 6.8% in the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock worth $569,800,000 after buying an additional 382,520 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ILMN has been the subject of a number of recent analyst reports. UBS Group reiterated a “neutral” rating and set a $135.00 price target on shares of Illumina in a report on Friday, February 6th. Evercore set a $150.00 price target on shares of Illumina in a report on Friday, February 6th. Robert W. Baird set a $137.00 price target on shares of Illumina in a report on Friday, February 6th. Guggenheim upped their price target on shares of Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Piper Sandler lowered their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a report on Monday, February 9th. Six investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $129.69.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.